Davis Polk advised Zai Lab Limited in connection with its follow-on offering of $230 million of American Depositary Shares representing 9,019,608 ordinary shares of the company. The ADSs are listed on the Nasdaq Global Market under the symbol “ZLAB.” 

Zai Lab is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and addressing unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

The Davis Polk corporate team included partner Li He, counsel-registered foreign lawyer Xuelin (Steve) Wang and registered foreign lawyer Jennifer Liu. Counsel Alon Gurfinkel and associates Veronica Davis and Jonathan Saltz provided tax advice. Associate J. Taylor Arabian provided 1940 Act advice. Members of the Davis Polk team are based in the New York, London and Hong Kong offices.

 

Copy link to share post